Entasis Therapeutics   Report issue

For profit Phase 1 Phase 3
Founded: Waltham MA United States (2015)
Status: Acquired by Innoviva (2022)

Organization Overview

First Clinical Trial
2015
NCT02298920
First Marketed Drug
2023
durlobactam (Xacduro)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ENTASIS THERAP | Entasis Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacteremia (Phase 3)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pyelonephritis (Phase 2)

Renal Insufficiency (Phase 1)

Urinary Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9